Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation awards and share price data relevant to those awards.
- Ordinary Share Price: £16.505 (Closing price on February 12, 2014)
- ADS Price: US$54.81 (Closing price on February 12, 2014)
Material Changes
The filing details changes in share interests for two PDMRs resulting from awards made on February 12, 2014:
- Mrs. V. Whyte: Received 11,800 Ordinary Shares.
- Mr. J. Ford: Received 6,740 American Depositary Shares (ADS).
Vesting of these awards is subject to meeting performance criteria over a three-year period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific insider transactions rather than a financial results report.
Investor Verification Checklist
- Verify the vesting conditions and performance criteria for the 2009 Performance Share Plan.
- Confirm the total number of shares awarded to PDMRs against the company's broader equity compensation plan limits.
- Review the company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial statements.